Stay updated on GH001 Trial in Treatment-resistant Depression Clinical Trial

Sign up to get notified when there's something new on the GH001 Trial in Treatment-resistant Depression Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the GH001 Trial in Treatment-resistant Depression Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.4%
    Check dated 2024-07-23T15:26:38.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T09:34:35.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-07-02T15:44:47.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the content on the webpage.
    Difference
    0.1%
    Check dated 2024-06-27T12:08:38.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-26T10:42:30.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus Genetics related topics: Depression FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Quadruple ( Participant Care Provider Investigator Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : GH001 - Part 1 GH001 is administered via inhalation, as an IDR consisting of up to 3 increasing doses of GH001 (6 mg, 12 mg, and 18 mg), on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a peak experience [PE]) at the previously administered dose. Drug : GH001 GH001 administered via inhalation Other Names: 5-Methoxy-N,N-dimethyltryptamine 5-MeO-DMT Mebufotenin Placebo Comparator : Placebo - Part 1 Placebo is administered via inhalation, as an IDR consisting of up to 3 doses of Placebo, on a single day. The second and third doses are only administered if the patient did not achieve intense psychoactive effects (a PE) at the previously administered dose. Drug : Placebo Placebo administered via inhalation Other : Open-Label Extension (OLE) - Part 2 Patients can receive up to five GH001 IDRs as needed during the OLE based on the patient's clinical response. Drug : GH001 GH001 administered via inhalation Other Names: 5-Methoxy-N,N-dimethyltryptamine 5-MeO-DMT Mebufotenin Primary Outcome Measures Outcome Measure Measure Description Time Frame Mean change in MADRS from Baseline to Day 7 The assessment is done with the MADRS, a diagnostic questionnaire with ten items for measuring the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item is scored from 0 to 6. The overall score ranges from 0 to 60. Baseline to Day 7 Keywords Provided by GH Research Ireland Limited Treatment-resistant depression Major depressive disorder Depression GH001 5-MeO-DMT 5-methoxy-N,N-dimethyltryptamine Mebufotenin Additional Relevant MeSH Terms Behavioral Symptoms Mood Disorders Mental Disorders Depression Depressive Disorder Depressive Disorder, Treatment-Resistant Hallucinogens Physiological Effects of Drugs Psychotropic Drugs Serotonin Antagonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Serotonin Receptor Agonists N,N-Dimethyltryptamine Plan to Share Individual Participant Data (IPD)? No Studies a U.S. FDA-Regulated Drug Product No Studies a U.S. FDA-Regulated Device Product No Revision: v2.9.1'
    Difference
    21%
    Check dated 2024-06-25T09:50:12.000Z thumbnail image

Stay in the know with updates to GH001 Trial in Treatment-resistant Depression Clinical Trial

Enter your email address, and we'll notify you when there's something new on the GH001 Trial in Treatment-resistant Depression Clinical Trial page.